Darla Miller

Phase 2 study of low‐dose clofarabine plus cytarabine for patients with higher‐risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents

H. Kantarjian, G. Garcia-Manero, S. Verstovsek, 2017, Cancer.

Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine.

M. Konopleva, K. Bhalla, T. Kadia, 2022, Leukemia research.

A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016 .

Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low- or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2015 .

A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia

M. Konopleva, Z. Estrov, M. Andreeff, 2022, Leukemia & lymphoma.

Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS)

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2014 .

Phase 1 Results of Bromodomain and Extraterminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.

K. Bhalla, G. Garcia-Manero, T. Kadia, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.